Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genomic Tests For Warfarin Could Gain Coverage With Study Participation

This article was originally published in The Pink Sheet Daily

Executive Summary

Under a CMS proposal, genomic testing to predict warfarin response would receive Medicare coverage in the context of a clinical trial comparing the frequency of five kinds of adverse events with and without the tests.
Advertisement

Related Content

Medicare Considers Coverage Policy For Genetic Warfarin Dosing Tests
Medicare Considers Coverage Policy For Genetic Warfarin Dosing Tests
Clinicians Split On Warfarin Gene Testing As A New Standard Of Care
Personalized Genetic Test Info Added To Warfarin Drug Labeling

Topics

Advertisement
UsernamePublicRestriction

Register

PS069408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel